Chinese CRO R&G buys into Medidata's trial tech

R&G Pharma Studies, a Chinese CRO, is deepening its relationship with clinical trial tech provider Medidata ($MDSO), adopting the company's cloud-based management system.

Headquartered in Beijing, R&G is buying into Medidata's clinical trial management system, or CTMS, becoming the first Chinese company to do so. Medidata bills its CTMS as an all-in-one offering that allows CROs and sponsors to manage trial sites, monitor results and dole out payments from anywhere in the world.

R&G first reached out to Medidata last year, adopting the firm's technology for electronic data capture and management, and the CRO's latest move gives Medidata a chance to expand the use of its banner products, the company said.

"China is a key market in (Asia Pacific's) expanding clinical trial landscape, and R&G is well positioned to support clinical innovation in the region," Medidata Vice President Edwin Ng said in a statement. "By pairing Medidata's agile, cloud-based technology with R&G's deep clinical expertise and industry insight, we look forward to fueling better, more strategic research across the region."

R&G is now among the roughly two-thirds of Medidata customers that use two or more of the company's products. In 2014, that number was below 60%, Medidata said.

- read the statement